March 19, 2018 / 10:37 AM / in 8 months

BRIEF-Knight Therapeutics Says ‍Will Have Exclusive Rights To Market And Sell Tenapanor In Canada​

March 19 (Reuters) - Ardelyx Inc:

* KNIGHT THERAPEUTICS - ‍LICENSE AGREEMENT WITH ARDELYX THAT PROVIDES KNIGHT WITH EXCLUSIVE RIGHTS TO COMMERCIALIZE TENAPANOR IN CANADA​

* KNIGHT THERAPEUTICS - ‍WILL PAY UP TO C$25 MILLION IN TOTAL PAYMENTS INCLUDING AN UPFRONT PAYMENT AND DEVELOPMENT AND SALES MILESTONES

* KNIGHT THERAPEUTICS INC - ‍KNIGHT WILL HAVE EXCLUSIVE RIGHTS TO MARKET AND SELL TENAPANOR IN CANADA​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below